| NCT ID | NCT04935021 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Second Affiliated Hospital, Zhejiang University, School of Medicine |
| Condition | Transthyroxine Amyloidosis Cardiomyopathy |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2021-06-01 |
| Primary Completion | 2031-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 100 participants in total. It began in 2021-06-01 with a primary completion date of 2031-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In this study, patients with ATTR-CM or gene carriers were selected to study the diagnosis and treatment, and long-term follow-up was conducted.
Eligibility Criteria
Inclusion Criteria: * Patients and gene carriers of ATTR-CM confirmed in the Second Affiliated Hospital of Zhejiang University School of Medicine, regardless of gender, age 18-90 years old; * Patients who have the ability to understand the test and can cooperate with investigators Exclusion Criteria: * Patients who unable to understand or unwilling to fill in informed consent forms or follow visitors
Frequently Asked Questions
Who can join the NCT04935021 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Transthyroxine Amyloidosis Cardiomyopathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT04935021 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT04935021 currently recruiting?
Yes, NCT04935021 is actively recruiting participants. Visit ClinicalTrials.gov or contact Second Affiliated Hospital, Zhejiang University, School of Medicine to inquire about joining.
Where is the NCT04935021 trial being conducted?
This trial is being conducted at Hangzhou, China.
Who is sponsoring the NCT04935021 clinical trial?
NCT04935021 is sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. The trial plans to enroll 100 participants.